Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q4 2016 · 10-K
Revenue$22.65M$22.65M+264.2% vs Q4 2015 Net Income-$23.20M-$23.20MN/M vs Q4 2015 EPS Diluted-$1.34-$1.34N/M vs Q4 2015 Operating Income-$57,409,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$52,445,000N/M Margins · derivedOperating margin-253.5%+404.2 pt vs Q4 2015
Net margin-102.4%+550.9 pt vs Q4 2015
ended Dec 31, 2016 · filed Feb 16, 2017 · 47 d after period end